bioAffinity Technologies, Inc. - What You Need to Know

Thinking about investing in bioAffinity Technologies? It is exciting to look at new biotech companies, but this one is currently in a high-stakes struggle to survive. Here is the breakdown in plain English.

1. What does this company actually do?

bioAffinity creates non-invasive tests to find early-stage cancer. Their main product, CyPath® Lung, uses a special lab test to spot lung cancer cells in mucus samples. The test uses a unique compound that makes cancer cells glow under a microscope. They run their own lab, Precision Pathology Laboratory Services (PPLS), to process these samples. Because they are just starting to sell their product, they rely almost entirely on this one lab to make money and keep running.

2. The "Red Alert" Situation

The company is fighting to stay on the Nasdaq stock exchange. They failed to meet Nasdaq’s rules for a $1.00 minimum share price and $2.5 million in stockholders' equity.

• The Deadline: Nasdaq gave the company until October 2, 2025, to fix their equity levels.
• The Reverse Split: To boost their share price and meet Nasdaq rules, they recently performed a 1-for-30 reverse stock split. This combined every 30 shares into one. While this raised the price per share, it did not change the actual value of the company.

3. What is this new offering?

The company is selling new shares at $2.50 each to raise about $4.1 million. Here is how the deal works:

• "Best Efforts" Only: The agent selling these shares does not have to sell all of them. If they sell fewer shares, the company gets less cash, which could hurt their ability to operate.
• The "Middleman" Cut: The company is paying the agent a fee of 8% of the total money raised. They are also paying the agent’s legal bills, which leaves even less cash for research and daily business.
• Immediate Dilution: This deal creates more shares, which reduces the percentage of the company you own.
• The "Warrant" Trap: The deal includes "Pre-Funded Warrants." These allow holders to buy more stock later at a very low price. These warrants could lead to even more shares being issued in the future, further reducing your ownership stake.

4. What are the main risks?

• "Going Concern" Warning: The company’s auditors have warned there is "substantial doubt" about the company’s ability to stay in business. There is a real risk they could run out of cash and shut down.
• Operational Fragility: The business relies on one single lab. If that lab has any technical or regulatory problems, the company stops making money immediately.
• The "Billing Nightmare": The company struggles to get insurance companies and government programs to pay for their tests. If they cannot prove their test is "medically necessary," they will struggle to become profitable.
• Tax Headaches: If you do not provide the correct tax ID or follow foreign asset reporting rules, the company may be forced to withhold 24% of your sale proceeds for the IRS.

5. The Bottom Line

You are looking at a company fighting for its life. They are selling new shares to stay on the Nasdaq, but this move reduces your ownership and costs them significant fees. There is no guarantee this money will keep them afloat, and the risk of being kicked off the exchange remains high.

Disclaimer: I am an AI, not a financial advisor. This company is in a precarious financial position. Never invest money you cannot afford to lose, and please read the official "Prospectus" on the SEC website before making any decisions.